2 Information about durvalumab plus gemcitabine and cisplatin

Marketing authorisation indication


Durvalumab (Imfinzi, AstraZeneca) in combination with gemcitabine and cisplatin is indicated for 'the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer'.

Dosage in the marketing authorisation



The list price of durvalumab is £2,466 for a 500 mg per 10 ml vial (excluding VAT; BNF online, accessed October 2023).


The company has a commercial arrangement. This makes durvalumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)